Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

4:14am EDT
Price Change (% chg)

-2.75p (-2.08%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for VEC.L


Vectura Group plc (Vectura) is a developer of therapies principally for the treatment of respiratory diseases. The Company is engaged in developing treatments for respiratory diseases. Vectura’s products target diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The Company’s pharmaceutical business... (more)


Beta: -0.21
Market Cap (Mil.): £531.20
Shares Outstanding (Mil.): 402.42
Dividend: --
Yield (%): --


  VEC.L Industry Sector
P/E (TTM): -- 33.37 34.07
EPS (TTM): -0.01 -- --
ROI: -1.08 18.15 17.40
ROE: -1.27 18.85 18.25
Search Stocks

BRIEF-Vectura says partner Novartis signs marketing deal with Pfizer UK

* Announcement of commercial arrangement with Pfizer UK to promote Ultibro Breezhaler and Seebri Breezhaler in United Kingdom Source text for Eikon: Further company coverage:

04 Sep 2014

BRIEF-Vectura performance from April to date in line with board's expectations

* Product pipeline is progressing in line with board's expectations

19 Aug 2014

BRIEF-Vectura says in US collaboration agreement for VR506 asthma therapy

* Announces a further US collaboration agreement with a leading international pharmaceutical company for VR506 asthma therapy

30 Jun 2014

UPDATE 2-Vectura revenue jumps on royalty push, sees more growth

* Shares rise as much as 3.5 pct (Adds CEO and analyst comments; updates share movement)

21 May 2014

Vectura revenue rises 20 pct on higher royalty payments

May 21 - Drug developer Vectura Group Plc reported a 20 percent rise in full-year revenue as it benefited from higher royalty payments for drugs it has licensed.

21 May 2014

BRIEF-Vectura Group revenue rises 20 pct

* FY revenue rises 20 percent to 36.5 million stg (2012/13: 30.5 million stg)

21 May 2014

BRIEF-Vectura to initiate study for asthama medicine Favolir in Europe

* Will initiate a pivotal study in Europe later this calendar year for Favolir, its investigational product for severe, uncontrolled asthma

11 Apr 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: Sadif Analytics Prime
Provider: Peel Hunt

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks